Radiation and immunotherapy combo shows promise for advanced nasopharyngeal cancer
NCT ID NCT06323239
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether combining two types of radiation (SBRT and low-dose radiation) with an immunotherapy drug (toripalimab) and chemotherapy can help control recurrent or metastatic nasopharyngeal carcinoma. The study will enroll 148 participants who have not received prior treatment for their advanced disease. The main goal is to see how long the cancer stays under control, while also monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (PD-1 antibody), gemcitabine, cisplatin, and radiation therapy (SBRT, LDRT, IMRT)
- What this could lead to
- If successful, this combination could offer a new treatment option to control recurrent or metastatic nasopharyngeal carcinoma, potentially improving survival and delaying disease progression.
- What could go wrong
- This is a small, early-phase (phase II) trial with no control group, so results may not be definitive. The combination of radiation, immunotherapy, and chemotherapy carries risks of significant side effects, and the treatment may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers